MK-677 vs Somatropin
How MK-677 and Somatropin compare — what each is, how strong the human evidence is for each, doses reported in research, the key risks, and 2026 US legal status. No universal winner.
MK-677 and Somatropin come up together when people are weighing similar options. Here's the honest side-by-side: what each is, how strong the human evidence is for each, the doses reported in research, the risks, and where each stands with the FDA as of 2026. There's no universal winner — scroll to the by-goal picks for which one fits which goal.
MK-677 vs Somatropin, point by point
Every dimension side by side — the honest differences, not a scoreboard.
| Dimension | MK-677 | Somatropin |
|---|---|---|
| What it is | Non-peptide small molecule; orally active growth hormone secretagogue (ghrelin-receptor agonist) | Recombinant human growth hormone (a 191-amino-acid protein hormone) |
| Class / category | GH secretagogues | GH secretagogues |
| Evidence tier | Human RCT · Mixed | Human RCT · Helped |
| Studied / approved for | Age-related decline in growth hormone; Muscle wasting / sarcopenia; Growth hormone deficiency (as LUM-201); Recovery after hip fracture | Pediatric growth failure due to growth hormone deficiency; Adult growth hormone deficiency; Short stature associated with Turner syndrome; Short stature associated with Noonan syndrome; Short stature in children born small for gestational age without catch-up growth; Idiopathic short stature; Growth failure associated with Prader-Willi syndrome |
| US regulatory status (2026) | research use only (as of Jul 2026) | fda approved (as of Jul 2026) — approved for Growth hormone deficiency and product-specific pediatric growth disorders |
| Doses reported in research | No established study doses | No established study doses |
| Registered trials (ClinicalTrials.gov) | 8 | No data |
| Banned in sport (WADA) | Yes — on the WADA prohibited list | Yes — on the WADA prohibited list |
| Key risks | MK-677 has more human safety data than almost any compound sold on the research market, and that data is a mixed bag. It reliably causes water retention, a bump in appetite, and higher blood sugar with lower insulin sensitivity. A trial in frail elderly hip-fracture patients was stopped early after more heart-failure events in the MK-677 group — a warning that matters most for older or cardiovascular-risk users. It is not an approved medicine, and long-term use in healthy adults is unstudied. | Somatropin has extensive human safety data in approved populations, but the risk depends on diagnosis, age and dose. Fluid retention, joint or muscle pain, tingling and impaired glucose tolerance are established adverse effects. Serious warnings include intracranial hypertension, pancreatitis, worsening diabetic retinopathy and tumor progression or recurrence in susceptible patients. |
- Evidence tier: A tier reflects how human the evidence is, not a promise the compound works.
MK-677 vs Somatropin: the two molecules
The 2D chemical structures, straight from PubChem — a quick way to see how similar (or not) the two actually are.
Which one fits which goal?
There's no universal winner here — the honest answer depends on what you're after. These picks are framed by goal, and each says why.
If you want an FDA-approved, prescribable option
Leans toward Somatropin
Somatropin is FDA-approved (as of Jul 2026); MK-677 is research use only in the US, so it isn't available as an approved prescription.
References
- 1.Ibutamoren (MK-677) — indexed research (PubMed, National Library of Medicine)
- 2.MK-677 in older adults — 2-year body-composition RCT (ClinicalTrials.gov NCT00474279)
- 3.MK-0677 for Alzheimer's disease — completed Phase 2 trial (ClinicalTrials.gov NCT00074529)
- 4.LUM-201 (ibutamoren) in children with growth hormone deficiency — Phase 3 (ClinicalTrials.gov NCT06948214)
- 5.FDA — drug approvals and dietary-supplement information
- 6.USADA / WADA Prohibited List — growth hormone secretagogues (S2)